Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapyAdrienne Luoma, Kai W. Wucherpfennig, Shengbao Suo et al.|Cell|2022Cited by 376
Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II TrialRavindra Uppaluri, Douglas R. Adkins, Dorina Kallogjeri et al.|Clinical Cancer Research|2020Cited by 368
Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell CarcinomaJonathan D. Schoenfeld, Robert I. Haddad, Glenn J. Hanna et al.|JAMA Oncology|2020Cited by 350
Frameshift events predict anti–PD-1/L1 response in head and neck cancerGlenn J. Hanna, Robert I. Haddad, Patrick H. Lizotte et al.|JCI Insight|2018Cited by 279
Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck CancerRavindra Uppaluri, Douglas Adkins, Robert I. Haddad et al.|New England Journal of Medicine|2025Cited by 277